Clozapine resistance: Augmentation strategies

European Neuropsychopharmacology

Volumn 22, Issue 3, 2012, Pages 165-182

  Porcelli, Stefano ^a   Balzarro, Beatrice ^a   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Clozapine; Clozapine augmentation; Lamotrigine; Risperidone; Super Refractory Schizophrenia; Ultra resistant schizophrenia

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMISULPRIDE; AMPAKINE; ARIPIPRAZOLE; CLOZAPINE; CYCLOSERINE; DONEPEZIL; FLUOXETINE; FLUVOXAMINE; GLYCINE; ICOSAPENTAENOIC ACID ETHYL ESTER; LAMOTRIGINE; LITHIUM; MAZINDOL; MEMANTINE; MIRTAZAPINE; MODAFINIL; NEUROLEPTIC AGENT; PLACEBO; RISPERIDONE; SARCOSINE; SERINE; SULPIRIDE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; ZIPRASIDONE;

ABDOMINAL DISCOMFORT; ABSENCE OF SIDE EFFECTS; AGITATION; AKATHISIA; ASTHENIA; BODY WEIGHT; BRADYKINESIA; COCHRANE LIBRARY; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FATIGUE; GLUCOSE BLOOD LEVEL; HEARTBURN; HUMAN; HYPERSALIVATION; HYPERTENSION; INSOMNIA; MEDLINE; MENTAL PATIENT; META ANALYSIS; METABOLIC DISORDER; METHODOLOGY; MOUTH DISEASE; NAUSEA; NEGATIVE SYNDROME; ORAL DYSKINESIA; ORTHOSTATIC INTOLERANCE; PARESTHESIA; PRIORITY JOURNAL; PSYCHOSIS; QT INTERVAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREMOR;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; HUMANS; RISPERIDONE; SCHIZOPHRENIA;

EID: 84856559290     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.08.005     Document Type: Review

References (116)

1. Akdede B.B., Anil Yagcioglu A.E., Alptekin K., Turgut T.I., Tumuklu M., Yazici M.K., Jayathilake K., Tunca Z., Gogus A., Meltzer H.Y. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J. Clin. Psychiatry 2006, 67:1912-1919.
2. Allen L., Tejera C. Treatment of clozapine-induced obsessive-compulsive symptoms with sertraline. Am. J. Psychiatry 1994, 151:1096-1097.
3. al-Semaan Y. Bromocriptine as adjunctive therapy to clozapine in treatment-resistant schizophrenia. Can. J. Psychiatry 1996, 41:484-485.
4. Anil Yagcioglu A.E., Kivircik Akdede B.B., Turgut T.I., Tumuklu M., Yazici M.K., Alptekin K., Ertugrul A., Jayathilake K., Gogus A., Tunca Z., Meltzer H.Y. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J. Clin. Psychiatry 2005, 66:63-72.
5. Assion H.J., Reinbold H., Lemanski S., Basilowski M., Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008, 41:24-28.
6. Bachmann C.J., Lehr D., Theisen F.M., Preiss M. Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review. Pharmacopsychiatry 2009, 42:153-157.
7. Bender S., Linka T., Wolstein J., Gehendges S., Paulus H.J., Schall U., Gastpar M. Safety and efficacy of combined clozapine-lithium pharmacotherapy. Int. J. Neuropsychopharmacol. 2004, 7:59-63.
8. Benedetti A., Di Paolo A., Lastella M., Casamassima F., Candiracci C., Litta A., Ciofi L., Danesi R., Lattanzi L., Del Tacca M., Cassano G.B. Augmentation of clozapine with aripiprazole in severe psychotic bipolar and schizoaffective disorders: a pilot study. Clin Pract Epidemiol Ment Health 2010, 6:30-35.
9. Berk M., Gama C.S., Sundram S., Hustig H., Koopowitz L., D'Souza R., Malloy H., Rowland C., Monkhouse A., Monkhouse A., Bole F., Sathiyamoorthy S., Piskulic D., Dodd S. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum. Psychopharmacol. 2009, 24:233-238.
10. Bloch Y., Pollack M., Mor I. Should the administration of ECT during clozapine therapy be contraindicated?. Br. J. Psychiatry 1996, 169:253-254.
11. Brenner H.D., Dencker S.J., Goldstein M.J., Hubbard J.W., Keegan D.L., Kruger G., Kulhanek F., Liberman R.P., Malm U., Midha K.K. Defining treatment refractoriness in schizophrenia. Schizophr. Bull. 1990, 16:551-561.
12. Buchanan R.W., Kirkpatrick B., Bryant N., Ball P., Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am. J. Psychiatry 1996, 153:1625-1627.
13. Buckley P., Miller A., Olsen J., Garver D., Miller D.D., Csernansky J. When symptoms persist: clozapine augmentation strategies. Schizophr. Bull. 2001, 27:615-628.
14. Carpenter W.T., Conley R.R., Buchanan R.W., Breier A., Tamminga C.A. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am. J. Psychiatry 1995, 152:827-832.
15. Carpenter W.T., Breier A., Buchanan R.W., Kirkpatrick B., Shepard P., Weiner E. Mazindol treatment of negative symptoms. Neuropsychopharmacology 2000, 23:365-374.
16. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 2001, 158:518-526.
17. Chang J.S., Ahn Y.M., Park H.J., Lee K.Y., Kim S.H., Kang U.G., Kim Y.S. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2008, 69:720-731.
18. Conley R.R., Carpenter W.T., Tamminga C.A. Time to clozapine response in a standardized trial. Am. J. Psychiatry 1997, 154:1243-1247.
19. Dardennes R.M., Al Anbar N.N., Rouillon F. Successful augmentation of clozapine-resistant treatment of schizophrenia with clonidine. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:724-725.
20. de Groot I.W., Heck A.H., van Harten P.N. Addition of risperidone to clozapine therapy in chronically psychotic inpatients. J. Clin. Psychiatry 2001, 62:129-130.
21. de Lucena D., Fernandes B.S., Berk M., Dodd S., Medeiros D.W., Pedrini M., Kunz M., Gomes F.A., Giglio L.F., Lobato M.I., Belmonte-de-Abreu P.S., Gama C.S. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J. Clin. Psychiatry 2009, 70:1416-1423.
22. Delle Chiaie R., Salviati M., Fiorentini S., Biondi M. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. Exp. Clin. Psychopharmacol. 2007, 15:563-568.
23. Demily C., Franck N. Gabapentin for ultra resistant schizophrenia with aggressive behavior. Schizophr. Res. 2008, 100:349-350.
24. Diaz P., Bhaskara S., Dursun S.M., Deakin B. Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. J. Clin. Psychopharmacol. 2005, 25:277-278.
25. Dursun S.M., Deakin J.F. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J. Psychopharmacol. 2001, 15:297-301.
26. Emsley R., Myburgh C., Oosthuizen P., van Rensburg S.J. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry 2002, 159:1596-1598.
27. Englisch S., Esser A., Enning F., Hohmann S., Schanz H., Zink M. Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol 2010, 30:437-440.
28. Evins A.E., Fitzgerald S.M., Wine L., Rosselli R., Goff D.C. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am. J. Psychiatry 2000, 157:826-828.
29. Fabrazzo M., La Pia S., Monteleone P., Esposito G., Pinto A., De Simone L., Bencivenga R., Maj M. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology 2002, 27:1050-1055.
30. Farber N.B., Newcomer J.W., Olney J.W. Glycine agonists: what can they teach us about schizophrenia?. Arch. Gen. Psychiatry 1999, 56:13-17.
31. Fenton W.S., Dickerson F., Boronow J., Hibbeln J.R., Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry 2001, 158:2071-2074.
32. Fink M. ECT and clozapine in schizophrenia. J. ECT 1998, 14:223-226.
33. Fleischhacker W.W., Hummer M., Kurz M., Kurzthaler I., Lieberman J.A., Pollack S., Safferman A.Z., Kane J.M. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J. Clin. Psychiatry 1994, 55(Suppl B):78-81.
34. Flynn S.W., Altman S., MacEwan G.W., Black L.L., Greenidge L.L., Honer W.G. Prolongation of clozapine-induced granulocytopenia associated with olanzapine. J. Clin. Psychopharmacol. 1997, 17:494-495.
35. Frankenburg F.R., Suppes T., McLean P.E. Combined clozapine and electroconvulsive therapy. Convuls. Ther. 1993, 9:176-180.
36. Freudenreich O., Goff D.C. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr. Scand. 2002, 106:323-330.
37. Freudenreich O., Henderson D.C., Walsh J.P., Culhane M.A., Goff D.C. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr. Res. 2007, 92:90-94.
38. Freudenreich O., Henderson D.C., Macklin E.A., Evins A.E., Fan X., Cather C., Walsh J.P., Goff D.C. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J. Clin. Psychiatry 2009, 70:1674-1680.
39. Friedman J., Ault K., Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol. Psychiatry 1997, 42:522-523.
40. Giegling I., Drago A., Schafer M., Moller H.J., Rujescu D., Serretti A. Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J Psychiatr Res 2010, 44:487-492.
41. Goff D.C., Tsai G., Manoach D.S., Flood J., Darby D.G., Coyle J.T. d-cycloserine added to clozapine for patients with schizophrenia. Am. J. Psychiatry 1996, 153:1628-1630.
42. Goff D.C., Henderson D.C., Evins A.E., Amico E. A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia. Biol. Psychiatry 1999, 45:512-514.
43. Goff D.C., Leahy L., Berman I., Posever T., Herz L., Leon A.C., Johnson S.A., Lynch G. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J. Clin. Psychopharmacol. 2001, 21:484-487.
44. Goff D.C., Keefe R., Citrome L., Davy K., Krystal J.H., Large C., Thompson T.R., Volavka J., Webster E.L. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J. Clin. Psychopharmacol. 2007, 27:582-589.
45. Goff D.C., Lamberti J.S., Leon A.C., Green M.F., Miller A.L., Patel J., Manschreck T., Freudenreich O., Johnson S.A. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008, 33:465-472.
46. Grunder G., Hippius H., Carlsson A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat. Rev. Drug Discov. 2009, 8:197-202.
47. Gupta S., Sonnenberg S.J., Frank B. Olanzapine augmentation of clozapine. Ann. Clin. Psychiatry 1998, 10:113-115.
48. Henderson D.C., Goff D.C. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J. Clin. Psychiatry 1996, 57:395-397.
49. Henderson D.C., Kunkel L., Nguyen D.D., Borba C.P., Daley T.B., Louie P.M., Freudenreich O., Cather C., Evins A.E., Goff D.C. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr. Scand. 2006, 113:142-147.
50. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 1999, 56:29-36.
51. Hindmarch I., Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Human Psychopharmacology 2010, 25:193-200.
52. Honer W.G., Thornton A.E., Chen E.Y., Chan R.C., Wong J.O., Bergmann A., Falkai P., Pomarol-Clotet E., McKenna P.J., Stip E., Williams R., MacEwan G.W., Wasan K., Procyshyn R. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J. Med. 2006, 354:472-482.
53. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. 1998, 30:193-208.
54. Josiassen R.C., Joseph A., Kohegyi E., Stokes S., Dadvand M., Paing W.W., Shaughnessy R.A. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry 2005, 162:130-136.
55. Kampf P., Agelink M.W., Naber D. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry 2005, 38:39-40.
56. Kane J.M. Treatment-resistant schizophrenic patients. J. Clin. Psychiatry 1996, 57(Suppl 9):35-40.
57. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
58. Kelly D.L., Conley R.R., Feldman S., Yu Y., McMahon R.P., Richardson C.M. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr. Q. 2006, 77:81-95.
59. Kho K.H., Blansjaar B.A., de Vries S., Babuskova D., Zwinderman A.H., Linszen D.H. Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia - an open label study. Eur. Arch. Psychiatry Clin. Neurosci. 2004, 254:372-379.
60. Kirkpatrick B., Buchanan R.W., Ross D.E., Carpenter W.T. A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry 2001, 58:165-171.
61. Kontaxakis V.P., Ferentinos P.P., Havaki-Kontaxaki B.J., Roukas D.K. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur. Psychiatry 2005, 20:409-415.
62. Kremer I., Vass A., Gorelik I., Bar G., Blanaru M., Javitt D.C., Heresco-Levy U. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol. Psychiatry 2004, 56:441-446.
63. Kronig M.H., Munne R.A., Szymanski S., Safferman A.Z., Pollack S., Cooper T., Kane J.M., Lieberman J.A. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am. J. Psychiatry 1995, 152:179-182.
64. Kupchik M., Spivak B., Mester R., Reznik I., Gonen N., Weizman A., Kotler M. Combined electroconvulsive-clozapine therapy. Clin. Neuropharmacol. 2000, 23:14-16.
65. Kuwilsky A., Krumm B., Englisch S., Dressing H., Zink M. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry 2010, 43:216-220.
66. Lane H.Y., Huang C.L., Wu P.L., Liu Y.C., Chang Y.C., Lin P.Y., Chen P.W., Tsai G. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol. Psychiatry 2006, 60:645-649.
67. Large C.H., Webster E.L., Goff D.C. The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl) 2005, 181:415-436.
68. Lerner V., Bergman J., Borokhov A., Loewenthal U., Miodownik C. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin. Neuropharmacol. 2005, 28:66-71.
69. Lieberman J.A., Safferman A.Z., Pollack S., Szymanski S., Johns C., Howard A., Kronig M., Bookstein P., Kane J.M. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am. J. Psychiatry 1994, 151:1744-1752.
70. Lu M.L., Lane H.Y., Chen K.P., Jann M.W., Su M.H., Chang W.H. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J. Clin. Psychiatry 2000, 61:594-599.
71. Lu M.L., Lane H.Y., Lin S.K., Chen K.P., Chang W.H. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J. Clin. Psychiatry 2004, 65:766-771.
72. Masiar S.J., Johns C.A. ECT following clozapine. Br. J. Psychiatry 1991, 158:135-136.
73. Masoudzadeh A., Khalilian A.R. Comparative study of clozapine, electroshock and the combination of ECT with clozapine in treatment-resistant schizophrenic patients. Pak. J. Biol. Sci. 2007, 10:4287-4290.
74. Meltzer H.Y., Bastani B., Kwon K.Y., Ramirez L.F., Burnett S., Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl) 1989, 99(Suppl):S68-S72.
75. Meltzer H.Y., Burnett S., Bastani B., Ramirez L.F. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp. Community Psychiatry 1990, 41:892-897.
76. Mitsonis C.I., Dimopoulos N.P., Mitropoulos P.A., Kararizou E.G., Katsa A.N., Tsakiris F.E., Katsanou M.N. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:373-377.
77. Munro J., Matthiasson P., Osborne S., Travis M., Purcell S., Cobb A.M., Launer M., Beer M.D., Kerwin R. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr. Scand. 2004, 110:292-298.
78. Muscatello M., Bruno A., Pandolfo G., Mico U., Bellinghieri P., Scimeca G., Cacciola M., Campolo D., Settineri S., Zoccali R. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study 2011, J Psychopharmacol.
79. Newman M.E., Gur E., Shapira B., Lerer B. Neurochemical mechanisms of action of ECS: evidence from in vivo studies. J. ECT 1998, 14:153-171.
80. Nielsen J., Damkier P., Lublin H., Taylor D. Optimizing clozapine treatment. Acta Psychiatrica Scandinavica 2011, 123:411-422.
81. Peet M., Horrobin D.F. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res. 2002, 36:7-18.
82. Perala J., Suvisaari J., Saarni S.I., Kuoppasalmi K., Isometsa E., Pirkola S., Partonen T., Tuulio-Henriksson A., Hintikka J., Kieseppa T., Harkanen T., Koskinen S., Lonnqvist J. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry 2007, 64:19-28.
83. Perry P.J., Miller D.D., Arndt S.V., Cadoret R.J. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am. J. Psychiatry 1991, 148:231-235.
84. Potkin S.G., Bera R., Gulasekaram B., Costa J., Hayes S., Jin Y., Richmond G., Carreon D., Sitanggan K., Gerber B., et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J. Clin. Psychiatry 1994, 55(Suppl B):133-136.
85. Potkin S.G., Jin Y., Bunney B.G., Costa J., Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am. J. Psychiatry 1999, 156:145-147.
86. Potter W.Z., Ko G.N., Zhang L.D., Yan W.W. Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology (Berl) 1989, 99(Suppl):S87-S91.
87. Rahman M.S., Grace J.J., Pato M.T., Priest B. Sertraline in the treatment of clozapine-induced obsessive-compulsive behavior. Am. J. Psychiatry 1998, 155:1629-1630.
88. Rajarethinam R., Gilani S., Tancer M., DeQuardo J. Augmentation of clozapine partial responders with conventional antipsychotics. Schizophr. Res. 2003, 60:97-98.
89. Remington G., Saha A., Chong S.A., Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005, 19:843-872.
90. Rosenheck R., Evans D., Herz L., Cramer J., Xu W., Thomas J., Henderson W., Charney D. How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophr. Bull. 1999, 25:709-719.
91. Rossler W., Salize H.J., van Os J., Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur. Neuropsychopharmacol. 2005, 15:399-409.
92. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Lobos C.A., Kissling W., Davis J.M., Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 2010, 123:225-233.
93. Schulte P. What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin. Pharmacokinet. 2003, 42:607-618.
94. Shiloh R., Zemishlany Z., Aizenberg D., Radwan M., Schwartz B., Dorfman-Etrog P., Modai I., Khaikin M., Weizman A. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br. J. Psychiatry 1997, 171:569-573.
95. Silver H., Kushnir M., Kaplan A. Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study. Biol. Psychiatry 1996, 40:671-674.
96. Small J.G., Klapper M.H., Malloy F.W., Steadman T.M. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J. Clin. Psychopharmacol. 2003, 23:223-228.
97. Sommer, I.E., Begemann, M.J., Temmerman, A., Leucht, S., 2011. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophrenia Bulletin.
98. Spina E., Avenoso A., Facciola G., Fabrazzo M., Monteleone P., Maj M., Perucca E., Caputi A.P. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int. Clin. Psychopharmacol. 1998, 13:141-145.
99. Stryjer R., Strous R., Bar F., Shaked G., Shiloh R., Rozencwaig S., Grupper D., Buchman N., Kotler M., Rabey J.M., Weizman A. Donepezil augmentation of clozapine monotherapy in schizophrenia patients: a double blind cross-over study. Hum. Psychopharmacol. 2004, 19:343-346.
100. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr. Res. 2009, 110:1-23.
101. Taylor D.M., Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J. Psychopharmacol. 2000, 14:409-418.
102. Taylor C.G., Flynn S.W., Altman S., Ehmann T., MacEwan G.W., Honer W.G. An open trial of risperidone augmentation of partial response to clozapine. Schizophr. Res. 2001, 48:155-158.
103. Tiihonen J., Hallikainen T., Ryynanen O.P., Repo-Tiihonen E., Kotilainen I., Eronen M., Toivonen P., Wahlbeck K., Putkonen A. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol. Psychiatry 2003, 54:1241-1248.
104. Tiihonen J., Halonen P., Wahlbeck K., Repo-Tiihonen E., Hyvarinen S., Eronen M., Putkonen H., Takala P., Mehtonen O.P., Puck M., Oksanen J., Koskelainen P., Joffe G., Aer J., Hallikainen T., Ryynanen O.P., Tupala E. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J. Clin. Psychiatry 2005, 66:1012-1015.
105. Tsai G.E., Yang P., Chung L.C., Tsai I.C., Tsai C.W., Coyle J.T. d-serine added to clozapine for the treatment of schizophrenia. Am. J. Psychiatry 1999, 156:1822-1825.
106. Usiskin S.I., Nicolson R., Lenane M., Rapoport J.L. Gabapentin prophylaxis of clozapine-induced seizures. Am. J. Psychiatry 2000, 157:482-483.
107. Weiner E., Conley R.R., Ball M.P., Feldman S., Gold J.M., Kelly D.L., Wonodi I., McMahon R.P., Buchanan R.W. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 2010, 35:2274-2283.
108. Wells G.A., Shea B., O'Connell D., Petersone J., Welch V., Losos M., Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-randomized Studies in Meta-analysis 2004.
109. Wetzel H., Anghelescu I., Szegedi A., Wiesner J., Weigmann H., Harter S., Hiemke C. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J. Clin. Psychopharmacol. 1998, 18:2-9.
110. Williams L., Newton G., Roberts K., Finlayson S., Brabbins C. Clozapine-resistant schizophrenia: a positive approach. Br. J. Psychiatry 2002, 181:184-187.
111. Wilson W.H. Time required for initial improvement during clozapine treatment of refractory schizophrenia. Am. J. Psychiatry 1996, 153:951-952.
112. Ziegenbein M., Wittmann G., Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clin. Drug Investig. 2006, 26:117-124.
113. Zink M., Knopf U., Henn F.A., Thome J. Combination of clozapine and amisulpride in treatment-resistant schizophrenia - case reports and review of the literature. Pharmacopsychiatry 2004, 37:26-31.
114. Zink M., Kuwilsky A., Krumm B., Dressing H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J. Psychopharmacol. 2009, 23:305-314.
115. Zoccali R., Muscatello M.R., Cedro C., Neri P., La Torre D., Spina E., Di Rosa A.E., Meduri M. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 2004, 19:71-76.
116. Zoccali R., Muscatello M.R., Bruno A., Cambria R., Mico U., Spina E., Meduri M. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr. Res. 2007, 93:109-116.